Roche Holding AG (RHHBY)

OTCMKTS · Delayed Price · Currency is USD
39.79
-0.29 (-0.71%)
Jul 21, 2025, 4:00 PM EDT
1.32%
Market Cap257.10B
Revenue (ttm)68.85B
Net Income (ttm)9.13B
Shares Outn/a
EPS (ttm)11.38
PE Ratio28.15
Forward PE12.86
Dividend0.87 (2.18%)
Ex-Dividend DateMar 28, 2025
Volume317,461
Average Volume1,138,872
Open39.95
Previous Close40.08
Day's Range39.67 - 40.16
52-Week Range34.10 - 44.31
Beta0.17
RSI45.37
Earnings DateJul 24, 2025

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]

Sector Healthcare
Founded 1896
Employees 103,249
Stock Exchange OTCMKTS
Ticker Symbol RHHBY
Full Company Profile

Financial Performance

In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.

Financial numbers in CHF Financial Statements

News

Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase IIb ALIENTO (n=1,301) and the ...

1 day ago - Business Wire

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolima...

1 day ago - GlobeNewsWire

Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Re...

3 days ago - Business Wire

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.

13 days ago - CNBC

Lomiko Metals Announces Ruisseau Graphite Project Exploration Update, La Roche Zone Extension and Fall Workplan

MONTREAL--(BUSINESS WIRE)--Lomiko Metals Inc. (TSX.V: LMR) (“Lomiko” or the “Company”) announces exploration results from the spring program at the Ruisseau graphite prospect and plans for the summer/...

21 days ago - Business Wire

Changes to the Roche Enlarged Corporate Executive Committee

Basel, 30 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Johannes (Hans) Clevers (1957), M.D., Ph.D., Head of Roche Pharma Research and Early Development (pRED) and member of the ...

22 days ago - GlobeNewsWire

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

On Sunday, Exelixis, Inc. (NASDAQ: EXEL) revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) combined with atezolizumab . The study includes patients with pr...

4 weeks ago - Benzinga

Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

Basel, 20 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today results from the phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab) administered subcutaneously in combinati...

4 weeks ago - GlobeNewsWire

Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio...

4 weeks ago - Business Wire

Genentech Provides Update on Phase III Verona Study

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study (NCT04401748) ...

5 weeks ago - Business Wire

Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

5 weeks ago - WSJ

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease

- Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease - - Prasinezumab is a potential first-in-clas...

5 weeks ago - Benzinga

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, a...

5 weeks ago - Business Wire

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Data from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease Prasinezumab is a potential first-in-class a...

5 weeks ago - Benzinga

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

Basel, 16 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-...

5 weeks ago - GlobeNewsWire

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscu...

5 weeks ago - GlobeNewsWire

Health Canada Authorizes PiaSky® (crovalimab for injection) As the First Monthly (Every Four Weeks) Subcutaneous Treatment for People With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PiaSky® is the first monthly (every four weeks) subcutaneous treatment for PNH in Canada with the option to self-administer following adequate training (1) PiaSky® (crovalimab for injection) has the p...

5 weeks ago - Benzinga

Access Medical Labs, a Subsidiary of Empresas Aries, Completes Historic Lab Expansion with Roche Diagnostics Systems

JUPITER, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- In a milestone rarely achieved in the clinical laboratory industry, Access Medical Labs — the largest private diagnostic lab in Florida — has completed...

5 weeks ago - GlobeNewsWire

$101.5 Bn Oncology Diagnostics Global Markets, 2023-2024 & 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche.

The global oncology diagnostics market is projected to grow from $77.6 billion in 2024 to $101.5 billion by 2029. Key growth drivers include rising cancer rates, R&D, new product launches, and expansi...

5 weeks ago - GlobeNewsWire